vs
Mativ Holdings, Inc.（MATV）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
Pediatrix Medical Group, Inc.的季度营收约是Mativ Holdings, Inc.的1.1倍（$493.8M vs $463.1M），Mativ Holdings, Inc.净利率更高（21.8% vs 6.8%，领先14.9%），Mativ Holdings, Inc.同比增速更快（1.0% vs -1.7%），过去两年Pediatrix Medical Group, Inc.的营收复合增速更高（-0.1% vs -3.8%）
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
MATV vs MD — 直观对比
营收规模更大
MD
是对方的1.1倍
$463.1M
营收增速更快
MATV
高出2.7%
-1.7%
净利率更高
MATV
高出14.9%
6.8%
两年增速更快
MD
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $463.1M | $493.8M |
| 净利润 | $100.8M | $33.7M |
| 毛利率 | 18.8% | — |
| 营业利润率 | 2.2% | 9.9% |
| 净利率 | 21.8% | 6.8% |
| 营收同比 | 1.0% | -1.7% |
| 净利润同比 | 6620.0% | 10.5% |
| 每股收益（稀释后） | $1.87 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATVMD
| Q4 25 | $463.1M | $493.8M | ||
| Q3 25 | $513.7M | $492.9M | ||
| Q2 25 | $525.4M | $468.8M | ||
| Q1 25 | $484.8M | $458.4M | ||
| Q4 24 | $458.6M | $502.4M | ||
| Q3 24 | $498.5M | $511.2M | ||
| Q2 24 | $523.8M | $504.3M | ||
| Q1 24 | $500.2M | $495.1M |
净利润MATVMD
| Q4 25 | $100.8M | $33.7M | ||
| Q3 25 | $-3.2M | $71.7M | ||
| Q2 25 | $-9.5M | $39.3M | ||
| Q1 25 | $-425.5M | $20.7M | ||
| Q4 24 | $1.5M | $30.5M | ||
| Q3 24 | $-20.8M | $19.4M | ||
| Q2 24 | $-1.4M | $-153.0M | ||
| Q1 24 | $-28.0M | $4.0M |
毛利率MATVMD
| Q4 25 | 18.8% | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 19.7% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 16.8% | — |
营业利润率MATVMD
| Q4 25 | 2.2% | 9.9% | ||
| Q3 25 | 3.1% | 13.8% | ||
| Q2 25 | 3.8% | 12.8% | ||
| Q1 25 | -88.8% | 7.0% | ||
| Q4 24 | 0.6% | 7.8% | ||
| Q3 24 | 1.4% | 6.6% | ||
| Q2 24 | 2.0% | -31.3% | ||
| Q1 24 | -2.8% | 3.2% |
净利率MATVMD
| Q4 25 | 21.8% | 6.8% | ||
| Q3 25 | -0.6% | 14.5% | ||
| Q2 25 | -1.8% | 8.4% | ||
| Q1 25 | -87.8% | 4.5% | ||
| Q4 24 | 0.3% | 6.1% | ||
| Q3 24 | -4.2% | 3.8% | ||
| Q2 24 | -0.3% | -30.3% | ||
| Q1 24 | -5.6% | 0.8% |
每股收益（稀释后）MATVMD
| Q4 25 | $1.87 | $0.40 | ||
| Q3 25 | $-0.06 | $0.84 | ||
| Q2 25 | $-0.18 | $0.46 | ||
| Q1 25 | $-7.82 | $0.24 | ||
| Q4 24 | $0.03 | $0.37 | ||
| Q3 24 | $-0.38 | $0.23 | ||
| Q2 24 | $-0.03 | $-1.84 | ||
| Q1 24 | $-0.52 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.2M | $375.2M |
| 总债务越低越好 | $1.0B | $570.5M |
| 股东权益账面价值 | $498.7M | $865.9M |
| 总资产 | $2.1B | $2.2B |
| 负债/权益比越低杠杆越低 | 2.07× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资MATVMD
| Q4 25 | $84.2M | $375.2M | ||
| Q3 25 | $97.1M | $340.1M | ||
| Q2 25 | $95.6M | $224.7M | ||
| Q1 25 | $84.0M | $99.0M | ||
| Q4 24 | $94.3M | $229.9M | ||
| Q3 24 | $162.2M | $103.8M | ||
| Q2 24 | $133.4M | $19.4M | ||
| Q1 24 | $128.9M | $8.0M |
总债务MATVMD
| Q4 25 | $1.0B | $570.5M | ||
| Q3 25 | $1.0B | $577.2M | ||
| Q2 25 | $1.1B | $583.9M | ||
| Q1 25 | $1.1B | $590.5M | ||
| Q4 24 | $1.1B | $597.1M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
股东权益MATVMD
| Q4 25 | $498.7M | $865.9M | ||
| Q3 25 | $397.4M | $890.7M | ||
| Q2 25 | $416.6M | $833.8M | ||
| Q1 25 | $428.2M | $789.2M | ||
| Q4 24 | $858.5M | $764.9M | ||
| Q3 24 | $882.3M | $732.5M | ||
| Q2 24 | $898.0M | $706.5M | ||
| Q1 24 | $906.9M | $856.2M |
总资产MATVMD
| Q4 25 | $2.1B | $2.2B | ||
| Q3 25 | $2.0B | $2.2B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.1B | $2.0B | ||
| Q4 24 | $2.4B | $2.2B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.6B | $2.0B | ||
| Q1 24 | $2.7B | $2.2B |
负债/权益比MATVMD
| Q4 25 | 2.07× | 0.66× | ||
| Q3 25 | 2.63× | 0.65× | ||
| Q2 25 | 2.66× | 0.70× | ||
| Q1 25 | 2.67× | 0.75× | ||
| Q4 24 | 1.30× | 0.78× | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 1.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $8.0M | — |
| 自由现金流率自由现金流/营收 | 1.7% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 0.19× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $93.8M | — |
8季度趋势，按日历期对齐
经营现金流MATVMD
| Q4 25 | $19.3M | $114.1M | ||
| Q3 25 | $72.8M | $137.3M | ||
| Q2 25 | $57.6M | $137.2M | ||
| Q1 25 | $-15.9M | $-117.5M | ||
| Q4 24 | $24.1M | $133.0M | ||
| Q3 24 | $37.6M | $91.8M | ||
| Q2 24 | $46.1M | $107.0M | ||
| Q1 24 | $-13.0M | $-125.2M |
自由现金流MATVMD
| Q4 25 | $8.0M | — | ||
| Q3 25 | $66.7M | — | ||
| Q2 25 | $48.9M | — | ||
| Q1 25 | $-29.8M | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $25.5M | — | ||
| Q2 24 | $37.4M | — | ||
| Q1 24 | $-25.1M | — |
自由现金流率MATVMD
| Q4 25 | 1.7% | — | ||
| Q3 25 | 13.0% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | -6.1% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | -5.0% | — |
资本支出强度MATVMD
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 2.4% | — |
现金转化率MATVMD
| Q4 25 | 0.19× | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | 16.07× | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
